retatrutide triple agonist glp-1 gip glucagon A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

Description

It allows brands to meet different eating occasions without depending on one format alone

Splitting doses to extend supply Another cost-reduction strategy involves splitting your tirzepatide dose across two injections per week rather than one

For Canadian patients exploring GLP-1 options, genetic insights combined with clinical evaluation can support a more personalized conversation with your healthcare provider about which GLP-1 formulation, dose pathway, and monitoring strategy may be most appropriate for your individual situation

During your visit, your provider will examine your skin under proper lighting, discuss your goals and concerns, and recommend a treatment plan with realistic timelines

Even a research study published by the National Institutes of Health notes that reduced food intake on GLP-1 medications can lead to poor nutrient status and muscle loss if left unaddressed, with daily protein needs generally falling between 1.2 and 2.0 grams per kilogram of body weight to help offset this